Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2

C Ellis Wisely, Huan Sheng, Theresa Heah, Terry Kim, C Ellis Wisely, Huan Sheng, Theresa Heah, Terry Kim

Abstract

Introduction: To describe the changes in endothelial cell density (ECD), the coefficient of variation (CV), the percentage of hexagonal cells (%HEX), and central corneal thickness (CCT) following 3 months of therapy with netarsudil 0.02%/latanoprost 0.005% fixed combination, and to compare these changes with those seen with netarsudil 0.02% or latanoprost 0.005% in eyes with ocular hypertension or open-angle glaucoma.

Methods: A subset of subjects enrolled in a Phase 3 evaluation of the intraocular pressure-lowering efficacy and safety of netarsudil 0.02%/latanoprost 0.005% fixed combination once daily (QD) versus each of its individual components underwent corneal endothelial cell imaging by specular microscopy and ultrasound pachymetry at baseline and following 3 months of therapy. Images were evaluated in masked fashion at an independent reading center. Changes from baseline to 3 months in ECD, CV, %HEX, and CCT were compared between treatment groups.

Results: Data from 415 subjects obtained at both baseline and Month 3 were included in this post hoc analysis. Changes from baseline to Month 3 in ECD, CV, and %HEX were clinically insignificant in all three groups, and the changes in the netarsudil/latanoprost fixed combination group demonstrated no statistical difference from those seen in the netarsudil and latanoprost groups. Mean CCT decreased more in the fixed combination group (- 6.4 µm) than in either the netarsudil group (- 3.3 µm, p = 0.0248) or the latanoprost group (- 1.2 µm, p < 0.0001).

Conclusions: Netarsudil 0.2%/latanoprost 0.005% fixed combination QD for 3 months in eyes with ocular hypertension or open-angle glaucoma had no clinically significant effects on endothelial cell density or morphology. The significant decrease in CCT in the fixed combination group compared to the two individual component groups may indicate that the potential effects of each drug on CCT are additive, although the magnitude of the observed effects is likely of negligible clinical significance. CLINICALTRIALS.

Gov identifier: NCT02674854.

Keywords: Glaucoma; Intraocular pressure; Latanoprost; Netarsudil; Netarsudil/latanoprost fixed combination; Ocular hypertension; Open-angle glaucoma.

Figures

Fig. 1
Fig. 1
Specular microscopy images at baseline (top) and Month 3 (bottom) from one eye each treated with netarsudil/latanoprost fixed combination (left), netarsudil (middle), or latanoprost (right). Respective endothelial cell densities at baseline and Month 3 were 2216.2 and 2096.6 cells/mm2 in the netarsudil/latanoprost eye, 3073.5 and 3091.0 cells/mm2 in the netarsudil eye, and 2601.5 and 2531.2 cells/mm2 in the latanoprost eye

References

    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013.
    1. United States Food and Drug Administration. Rhopressa (netarsudil) Ophthalmic Solution. . Accessed 22 Jan 2019.
    1. Dasso L, Al-Khaled T, Sonty S, Aref AA. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clin Ophthalmol. 2018;12:1939–1944. doi: 10.2147/OPTH.S154001.
    1. Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure, the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104. doi: 10.1016/j.ajo.2019.03.002.
    1. Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34:380–386. doi: 10.1089/jop.2017.0138.
    1. Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) Am J Ophthalmol. 2018;186:116–127. doi: 10.1016/j.ajo.2017.11.019.
    1. Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2) Am J Ophthalmol. 2019;200:130–137. doi: 10.1016/j.ajo.2019.01.003.
    1. Double-masked study of PG324 ophthalmic solution in patients with glaucoma or ocular hypertension. . Accessed 3 Mar 2019.
    1. Double-masked study of PG324 ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. . Accessed 26 Jan 2019.
    1. Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019 (in press).
    1. Safety and efficacy study of PG324 (netarsudil/latanoprost 0.02%/0.005%) ophthalmic solution compared to GANFORT® ophthalmic solution in open angle glaucoma or ocular hypertension. . Accessed 3 Mar 2019.
    1. Benetz BA, Gal RL, Ruedy KJ, et al. Specular microscopy ancillary study methods for donor endothelial cell density determination of Cornea Donor Study images. Curr Eye Res. 2006;31:319–327. doi: 10.1080/02713680500536738.
    1. Nakagawa H, Koizumi N, Okumura N, Suganami H, Kinoshita S. Morphological changes of human corneal endothelial cells after rho-associated kinase inhibitor eye drop (ripasudil) administration: a prospective open-label clinical study. PLoS ONE. 2015;10:e0136802. doi: 10.1371/journal.pone.0136802.
    1. Yoo R, Choi YA, Cho BJ. Change in central corneal thickness after the discontinuation of latanoprost in normal tension glaucoma–change in central corneal thickness after stop of latanoprost. J Ocul Pharmacol Ther. 2017;33:57–61. doi: 10.1089/jop.2016.0036.
    1. Kim HJ, Cho BJ. Long-term effect of latanoprost on central corneal thickness in normal tension glaucoma. J Ocul Pharmacol Ther. 2011;27:73–76. doi: 10.1089/jop.2010.0071.
    1. Lee H, Cho BJ. Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results. J Ocul Pharmacol Ther. 2015;31:152–155. doi: 10.1089/jop.2014.0109.
    1. Maruyama Y, Mori K, Ikeda Y, Ueno M, Kinoshita S. Effects of long-term topical prostaglandin therapy on central corneal thickness. J Ocul Pharmacol Ther. 2014;30:440–444. doi: 10.1089/jop.2013.0196.
    1. Zhong Y, Shen X, Yu J, Tan H, Cheng Y. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea. 2011;30:861–864. doi: 10.1097/ICO.0b013e3182000c27.
    1. Viswanathan D, Goldberg I, Graham SL. Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin Exp Ophthalmol. 2013;41:348–354. doi: 10.1111/j.1442-9071.2012.02870.x.
    1. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. Arch Ophthalmol. 2010;128:466–471. doi: 10.1001/archophthalmol.2010.40.
    1. Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32:1167–1170. doi: 10.1097/ICO.0b013e318285475d.
    1. Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Investig Ophthalmol Vis Sci. 2013;54:2493–2502. doi: 10.1167/iovs.12-11320.
    1. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000;57:976–983.
    1. Meekins LC, Rosado-Adames N, Maddala R, Zhao JJ, Rao PV, Afshari NA. Corneal endothelial cell migration and proliferation enhanced by Rho kinase (ROCK) inhibitors in in vitro and in vivo models. Investig Ophthalmol Vis Sci. 2016;57:6731–6738. doi: 10.1167/iovs.16-20414.
    1. Goldstein AS, Aldrich BT, Skeie JM, et al. Assessing the effects of ripasudil, a novel Rho kinase inhibitor, on human corneal endothelial cell health. J Ocul Pharmacol Ther. 2018 doi: 10.1089/jop.2018.0063.
    1. Okumura N, Okazaki Y, Inoue R, et al. Effect of the Rho-associated kinase inhibitor eye drop (ripasudil) on corneal endothelial wound healing. Investig Ophthalmol Vis Sci. 2016;57:1284–1292. doi: 10.1167/iovs.15-18586.
    1. Okumura N, Nakano S, Kay EP, et al. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Investig Ophthalmol Vis Sci. 2014;55:318–329. doi: 10.1167/iovs.13-12225.
    1. Okumura N, Koizumi N, Ueno M, et al. The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction. Cornea. 2011;30(Suppl 1):S54–S59. doi: 10.1097/ICO.0b013e3182281ee1.
    1. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006–1009. doi: 10.1136/bjo.2010.194571.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅